CN110346565A - PPR virus antibody assay kit - Google Patents
PPR virus antibody assay kit Download PDFInfo
- Publication number
- CN110346565A CN110346565A CN201810310284.2A CN201810310284A CN110346565A CN 110346565 A CN110346565 A CN 110346565A CN 201810310284 A CN201810310284 A CN 201810310284A CN 110346565 A CN110346565 A CN 110346565A
- Authority
- CN
- China
- Prior art keywords
- seq
- kit
- polypeptide
- des petits
- peste des
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000700605 Viruses Species 0.000 title abstract description 8
- 238000003149 assay kit Methods 0.000 title abstract 2
- 229920001184 polypeptide Polymers 0.000 claims abstract description 110
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 110
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 109
- 238000001514 detection method Methods 0.000 claims abstract description 51
- 239000007787 solid Substances 0.000 claims abstract description 26
- 241001428894 Small ruminant morbillivirus Species 0.000 claims description 67
- 239000012472 biological sample Substances 0.000 claims description 27
- 238000002360 preparation method Methods 0.000 claims description 19
- 241001494479 Pecora Species 0.000 claims description 17
- 241000283707 Capra Species 0.000 claims description 14
- 208000007634 Peste-des-Petits-Ruminants Diseases 0.000 claims description 12
- 210000002966 serum Anatomy 0.000 claims description 10
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 5
- 241000282849 Ruminantia Species 0.000 claims description 5
- 210000004369 blood Anatomy 0.000 claims description 5
- 239000008280 blood Substances 0.000 claims description 5
- 210000002381 plasma Anatomy 0.000 claims description 4
- 229960005486 vaccine Drugs 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000969 carrier Substances 0.000 abstract 2
- 238000000034 method Methods 0.000 description 30
- 230000035945 sensitivity Effects 0.000 description 29
- 201000010099 disease Diseases 0.000 description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 18
- 238000002965 ELISA Methods 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 230000010530 Virus Neutralization Effects 0.000 description 6
- 239000013642 negative control Substances 0.000 description 6
- 238000004140 cleaning Methods 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 241000283690 Bos taurus Species 0.000 description 3
- 206010035148 Plague Diseases 0.000 description 3
- 241000607479 Yersinia pestis Species 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 230000002327 eosinophilic effect Effects 0.000 description 3
- 210000003000 inclusion body Anatomy 0.000 description 3
- 208000013435 necrotic lesion Diseases 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 238000009007 Diagnostic Kit Methods 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 241000711897 Rinderpest morbillivirus Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- MXDOAJQRJBMGMO-FJXKBIBVSA-N Thr-Pro-Gly Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O MXDOAJQRJBMGMO-FJXKBIBVSA-N 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 108010013835 arginine glutamate Proteins 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000000120 cytopathologic effect Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 210000002200 mouth mucosa Anatomy 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 208000003265 stomatitis Diseases 0.000 description 2
- XVZCXCTYGHPNEM-IHRRRGAJSA-N (2s)-1-[(2s)-2-[[(2s)-2-amino-4-methylpentanoyl]amino]-4-methylpentanoyl]pyrrolidine-2-carboxylic acid Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(O)=O XVZCXCTYGHPNEM-IHRRRGAJSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 description 1
- PVSNBTCXCQIXSE-JYJNAYRXSA-N Arg-Arg-Phe Chemical compound NC(=N)NCCC[C@H](N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 PVSNBTCXCQIXSE-JYJNAYRXSA-N 0.000 description 1
- NABSCJGZKWSNHX-RCWTZXSCSA-N Arg-Arg-Thr Chemical compound NC(N)=NCCC[C@@H](C(=O)N[C@@H]([C@H](O)C)C(O)=O)NC(=O)[C@@H](N)CCCN=C(N)N NABSCJGZKWSNHX-RCWTZXSCSA-N 0.000 description 1
- AUFHLLPVPSMEOG-YUMQZZPRSA-N Arg-Gly-Glu Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(O)=O AUFHLLPVPSMEOG-YUMQZZPRSA-N 0.000 description 1
- KXOPYFNQLVUOAQ-FXQIFTODSA-N Arg-Ser-Ala Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O KXOPYFNQLVUOAQ-FXQIFTODSA-N 0.000 description 1
- HJRBIWRXULGMOA-ACZMJKKPSA-N Asn-Gln-Asp Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O HJRBIWRXULGMOA-ACZMJKKPSA-N 0.000 description 1
- QXOPPIDJKPEKCW-GUBZILKMSA-N Asn-Pro-Arg Chemical compound C1C[C@H](N(C1)C(=O)[C@H](CC(=O)N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O QXOPPIDJKPEKCW-GUBZILKMSA-N 0.000 description 1
- RYKWOUUZJFSJOH-FXQIFTODSA-N Asp-Gln-Glu Chemical compound C(CC(=O)N)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](CC(=O)O)N RYKWOUUZJFSJOH-FXQIFTODSA-N 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- CGVWDTRDPLOMHZ-FXQIFTODSA-N Gln-Glu-Asp Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O CGVWDTRDPLOMHZ-FXQIFTODSA-N 0.000 description 1
- OGMQXTXGLDNBSS-FXQIFTODSA-N Glu-Ala-Gln Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(O)=O OGMQXTXGLDNBSS-FXQIFTODSA-N 0.000 description 1
- ITYRYNUZHPNCIK-GUBZILKMSA-N Glu-Ala-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O ITYRYNUZHPNCIK-GUBZILKMSA-N 0.000 description 1
- GRHXUHCFENOCOS-ZPFDUUQYSA-N Glu-Ile-Met Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCSC)C(=O)O)NC(=O)[C@H](CCC(=O)O)N GRHXUHCFENOCOS-ZPFDUUQYSA-N 0.000 description 1
- UPOJUWHGMDJUQZ-IUCAKERBSA-N Gly-Arg-Arg Chemical compound NC(=N)NCCC[C@H](NC(=O)CN)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O UPOJUWHGMDJUQZ-IUCAKERBSA-N 0.000 description 1
- MBOAPAXLTUSMQI-JHEQGTHGSA-N Gly-Glu-Thr Chemical compound [H]NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O MBOAPAXLTUSMQI-JHEQGTHGSA-N 0.000 description 1
- WDEHMRNSGHVNOH-VHSXEESVSA-N Gly-Lys-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCCN)NC(=O)CN)C(=O)O WDEHMRNSGHVNOH-VHSXEESVSA-N 0.000 description 1
- JRYQSFOFUFXPTB-RWRJDSDZSA-N Ile-Gln-Thr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)N JRYQSFOFUFXPTB-RWRJDSDZSA-N 0.000 description 1
- WNGVUZWBXZKQES-YUMQZZPRSA-N Leu-Ala-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(O)=O WNGVUZWBXZKQES-YUMQZZPRSA-N 0.000 description 1
- XVZCXCTYGHPNEM-UHFFFAOYSA-N Leu-Leu-Pro Natural products CC(C)CC(N)C(=O)NC(CC(C)C)C(=O)N1CCCC1C(O)=O XVZCXCTYGHPNEM-UHFFFAOYSA-N 0.000 description 1
- IEWBEPKLKUXQBU-VOAKCMCISA-N Leu-Leu-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O IEWBEPKLKUXQBU-VOAKCMCISA-N 0.000 description 1
- IDGZVZJLYFTXSL-DCAQKATOSA-N Leu-Ser-Arg Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCN=C(N)N IDGZVZJLYFTXSL-DCAQKATOSA-N 0.000 description 1
- KLSUAWUZBMAZCL-RHYQMDGZSA-N Leu-Thr-Pro Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(O)=O KLSUAWUZBMAZCL-RHYQMDGZSA-N 0.000 description 1
- 101710169105 Minor spike protein Proteins 0.000 description 1
- 101710081079 Minor spike protein H Proteins 0.000 description 1
- 241000712045 Morbillivirus Species 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- 241000282943 Odocoileus Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000711504 Paramyxoviridae Species 0.000 description 1
- 206010035742 Pneumonitis Diseases 0.000 description 1
- XKHCJJPNXFBADI-DCAQKATOSA-N Pro-Asp-Lys Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)O XKHCJJPNXFBADI-DCAQKATOSA-N 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 206010039424 Salivary hypersecretion Diseases 0.000 description 1
- BYIROAKULFFTEK-CIUDSAMLSA-N Ser-Asp-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CO BYIROAKULFFTEK-CIUDSAMLSA-N 0.000 description 1
- FZXOPYUEQGDGMS-ACZMJKKPSA-N Ser-Ser-Gln Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(O)=O FZXOPYUEQGDGMS-ACZMJKKPSA-N 0.000 description 1
- 239000006180 TBST buffer Substances 0.000 description 1
- CEXFELBFVHLYDZ-XGEHTFHBSA-N Thr-Arg-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(O)=O CEXFELBFVHLYDZ-XGEHTFHBSA-N 0.000 description 1
- TZJSEJOXAIWOST-RHYQMDGZSA-N Thr-Lys-Arg Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(O)=O)CCCN=C(N)N TZJSEJOXAIWOST-RHYQMDGZSA-N 0.000 description 1
- BDGBHYCAZJPLHX-HJGDQZAQSA-N Thr-Lys-Asn Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O BDGBHYCAZJPLHX-HJGDQZAQSA-N 0.000 description 1
- CVUDMNSZAIZFAE-TUAOUCFPSA-N Val-Arg-Pro Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@@H]1C(=O)O)N CVUDMNSZAIZFAE-TUAOUCFPSA-N 0.000 description 1
- CVUDMNSZAIZFAE-UHFFFAOYSA-N Val-Arg-Pro Natural products NC(N)=NCCCC(NC(=O)C(N)C(C)C)C(=O)N1CCCC1C(O)=O CVUDMNSZAIZFAE-UHFFFAOYSA-N 0.000 description 1
- CELJCNRXKZPTCX-XPUUQOCRSA-N Val-Gly-Ala Chemical compound CC(C)[C@H](N)C(=O)NCC(=O)N[C@@H](C)C(O)=O CELJCNRXKZPTCX-XPUUQOCRSA-N 0.000 description 1
- CPGJELLYDQEDRK-NAKRPEOUSA-N Val-Ile-Ala Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H](N)C(C)C)C(=O)N[C@@H](C)C(O)=O CPGJELLYDQEDRK-NAKRPEOUSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 108010005233 alanylglutamic acid Proteins 0.000 description 1
- KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 108010018691 arginyl-threonyl-arginine Proteins 0.000 description 1
- 108010093581 aspartyl-proline Proteins 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000005178 buccal mucosa Anatomy 0.000 description 1
- 238000005056 compaction Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 208000026500 emaciation Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 108010055341 glutamyl-glutamic acid Proteins 0.000 description 1
- 108010027668 glycyl-alanyl-valine Proteins 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000013408 indirect enzyme-linked immunoassay Methods 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 210000001739 intranuclear inclusion body Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000003254 palate Anatomy 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 229960004545 plague vaccines Drugs 0.000 description 1
- 108010014614 prolyl-glycyl-proline Proteins 0.000 description 1
- 108010007513 prolyl-glycyl-prolyl-leucine Proteins 0.000 description 1
- 108010004914 prolylarginine Proteins 0.000 description 1
- 108010029020 prolylglycine Proteins 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 208000026451 salivation Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 210000003501 vero cell Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54306—Solid-phase reaction mechanisms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/115—Paramyxoviridae, e.g. parainfluenza virus
- G01N2333/12—Mumps virus; Measles virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A40/00—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
- Y02A40/70—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in livestock or poultry
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
Abstract
The present invention relates to PPR virus antibody assay kits.Detection kit of the invention includes one or more solid carriers, and particular polypeptide or the particular polypeptide combination being independently connected on one or more of solid carriers.
Description
Technical Field
The invention mainly relates to a diagnostic kit and a diagnostic method for animals. In particular, the invention relates to a kit for detecting the presence or absence of antibodies against peste des petits ruminants virus in a biological sample of biological origin from a subject.
Background
Peste des petits ruminants (PPR) is commonly called sheep plague, also called peste des petits ruminants pseudoplague (pseudocardipole), pneumoenteritis (pneumoenteritis) and stomatitis-pneumonitis complex disease, is an acute viral infectious disease caused by peste des petits ruminants virus, mainly infects peste ruminants, and is characterized by fever, stomatitis, diarrhea and pneumonia.
The disease occurs on the coast of ivory for the first time in 1942, and then, the disease is reported in Saibogal, Ganna, Dougo, Beining and the like in Africa, and the disease also occurs in sheep and goats in Nigeria and causes great loss. This disease has also been reported in several countries in asia, and according to the world animal health Organization (OIE) report in 1993 "world animal health", goats in bangladesh have developed this disease, while sheep in parts of indian dela and maharashtra have developed a disease similar to cattle plague, and finally have been diagnosed as peste des petits ruminants, after which infection has also been reported in tamierra. In 1993, Peste des petits ruminants were reported for the first time in Israel, the source of infection was unknown, and to prevent the spread of the disease, Israel inoculated cattle plague vaccines to sheep and goats in northern regions. In 1992, this disease-specific antibody was found in jordan sheep and goats, and in 1993, 11 clinical cases occurred in farms, and more than 100 sheep and goats died. In 1993, 133 cases were first discovered by saudi arabia. In 2007 in 7 months, the epidemic disease is introduced into Tibet regions of China for the first time.
Peste des petits ruminants virus belongs to the genus Paramyxoviridae and the genus morbillivirus. Has similar physical, chemical and immunological properties with Rinderpest virus. Viruses are polymorphic and are generally roughly spherical in shape. The virus particles are larger than Rinderpest virus, and the nucleocapsid is a spiral hollow rod-shaped and characteristic subunit and is provided with an envelope. The virus can proliferate on testis cells and Vero cells of fetal sheep kidney, fetal sheep and newborn sheep, and generate cytopathic effect (CPE) to form syncytial.
The disease mainly infects small ruminants such as goats, sheep, white tailed deer and the like, and is prevalent in western, middle and parts of asia of africa. In epidemic areas, the disease occurs sporadically, and epidemic can occur when susceptible animals increase. The disease is mainly infected by direct contact, and the secretion and excrement of the sick livestock are sources of infection, so that the sick sheep in the subclinical diagnosis type are particularly dangerous. The incubation period of Peste des petits ruminants is 4-5 days, and the longest period is 21 days. The natural onset is seen only in goats and sheep. The goat has serious disease, and the sheep occasionally has serious disease. The lips of some recovered goats developed aphthous lesions. The clinical symptoms of the infected animals are similar to those of cattle plague. The acute body temperature can be raised to 41 ℃ and maintained for 3-5 days. The infected animals have dysphoria, dull hair, dry mouth and nose, and anorexia. Mucus flows through purulent rhinorrhea and smelly gas is exhaled. In the first 4 days of fever, the oral mucosa becomes engorged with blood, the buccal mucosa undergoes extensive damage, causing salivation, and then necrotic lesions appear, and the oral mucosa begins to appear as small rough red superficial necrotic lesions, and later turns pink, and the infected site includes lower lip, lower gum, and the like. Severe cases can be seen where necrotic lesions spread to the pad, palate, cheeks and papillae, tongue, etc. In the later period, watery diarrhea with blood, severe dehydration, emaciation and body temperature reduction follow. Cough and abnormal breathing occur. The incidence rate is up to 100%, the mortality rate is 100% in severe outbreaks, and the mortality rate is not more than 50% in mild outbreaks. The serious morbidity and mortality of the young animals are high, and the disease is a disease defined in China.
The virus has special affinity to gastrointestinal tract lymphocyte and epithelial cell, so that it can cause characteristic pathological changes. Eosinophilic cytoplasmic inclusion bodies and multinucleated giant cells are typically present in infected cells. In lymphoid tissues, peste des petits ruminants virus can cause lymphocyte necrosis. Spleen, tonsil, and lymph node cells were destroyed. Multinucleated giant cells containing eosinophilic cytoplasmic inclusion bodies appeared with few intranuclear inclusion bodies. In the digestive system, the virus causes necrosis of epithelial cells deep in the markia layer, infected cells generate nuclear compaction and nuclear rupture, and multinucleated giant cells containing eosinophilic plasma inclusion bodies are formed in the epidermal germinal layer.
At present, no effective method for treating peste des petits ruminants exists, and control can be performed only by adopting methods of vaccination, killing after epidemic situations occur and regular serum monitoring. Therefore, serological diagnosis of the disease and evaluation and monitoring of vaccine immune effect are important.
The peste des petits ruminants virus antibody detection methods recommended by the world animal health organization mainly include Virus Neutralization Test (VNT) and enzyme-linked immunoassay (ELISA). The detection result of the virus neutralization test method is accurate and is a gold standard for detecting the peste des petits ruminants virus, but the method has long detection time and is not suitable for detecting a large number of samples. In contrast, enzyme-linked immunoassay has high specificity and sensitivity, has a shorter detection time than virus neutralization tests, and is suitable for detecting a large number of samples, and therefore, is widely applied to the detection of peste des petits ruminants virus antibodies.
The enzyme-linked immunoassay method for detecting the peste des petits ruminants virus antibody mainly comprises competitive enzyme-linked immunoassay (c-ELISA), blocking enzyme-linked immunoassay (b-ELISA) and indirect enzyme-linked immunoassay (indirect ELISA). The c-ELISA and the b-ELISA have higher specificity and sensitivity, and are generally accepted methods for detecting peste des petits ruminants virus antibodies in clinic, for example, the c-ELISA method is adopted by a peste des petits ruminants diagnostic kit of a French BIRAD laboratory which is commonly used internationally. However, both c-ELISA and b-ELISA need monoclonal antibody, which results in greatly increased detection cost; furthermore, c-ELISA and b-ELISA are cumbersome to operate, long in detection time (although already shortened relative to VNT), and complex in criteria. On the other hand, the conventional indirect ELISA detects antibodies in serum using intact proteins (e.g., H protein, N protein, F protein, etc.) or recombinant proteins derived from Peste des petits ruminants virus as a coating antigen at a cost lower than that of c-ELISA and b-ELISA; however, since this method uses the intact protein as an antigen, erroneous recognition and non-specific recognition of the antibody easily occur, and thus, its specificity and sensitivity are inferior to those of c-ELISA and b-ELISA.
Therefore, it is necessary to develop a peste des petits ruminants virus antibody detection kit with low detection cost, short detection time, simple operation, and high specificity and sensitivity.
Disclosure of Invention
In view of the problems in the prior art, the present invention aims to provide a peste des petits ruminants virus antibody detection kit with low detection cost, short detection time, simple operation, high specificity and sensitivity, and a polypeptide or a polypeptide combination capable of being used for preparing the kit.
The indirect ELISA method based on epitope polypeptide uses epitope polypeptide (single polypeptide of 20 amino acids usually only contains one epitope) as coating antigen. The inventor finds that: the sensitivity of the method is low, and the sensitivity of a single polypeptide generally does not exceed 50%; the polypeptide with high sensitivity also has high false positive rate, namely low specificity. If the epitope polypeptide with high sensitivity and specificity can be found, the defects of the traditional indirect ELISA can be overcome, and a peste des petits ruminants virus antibody detection kit with the specificity and the sensitivity comparable to those of c-ELISA and b-ELISA and even higher is developed.
The inventors have made intensive studies to solve the above-mentioned technical problems and found that SEQ ID NO: 1, the sensitivity and the specificity of the polypeptide used for detecting the peste des petits ruminants virus antibody are respectively 70.2% and 99.4%. In particular, when using SEQ ID NO: 1 and the polypeptide shown in SEQ ID NO: 2, when the polypeptide combination is used for detecting the peste des petits ruminants virus antibody, the sensitivity is 88.7 percent, and the specificity is 94.9 percent; and when using SEQ ID NO: 1 and the polypeptide shown in SEQ ID NO: 3, when the polypeptide combination is used for detecting the peste des petits ruminants virus antibody, the sensitivity is 87.2 percent, and the specificity is 91.3 percent; completely comparable to the c-ELISA method and the b-ELISA method.
The inventors have also found that when using SEQ ID NO: 1 and the polypeptide shown in SEQ ID NO: 4, when the polypeptide combination is used for detecting the peste des petits ruminants virus antibody, the sensitivity is 86.5 percent, and the specificity is 95.2 percent; and when using SEQ ID NO: 1 and the polypeptide shown in SEQ ID NO: 5, when the polypeptide combination is used for detecting the peste des petits ruminants virus antibody, the sensitivity is 85.7 percent, and the specificity is 94.4 percent; completely comparable to the c-ELISA method and the b-ELISA method.
The inventors have also found that when using SEQ ID NO: 1 and the polypeptide shown in SEQ ID NO: 6, when the polypeptide combination detects the peste des petits ruminants virus antibody, the sensitivity is 85 percent, and the specificity is 92.7 percent. More preferably, when the peptide of SEQ ID NO: 1, SEQ ID NO: 6 and the polypeptide of SEQ ID NO: 7, when the polypeptide combination shown in the specification is used for detecting the peste des petits ruminants virus antibody, the sensitivity is 89%, and the specificity is 89.9%; completely comparable to the c-ELISA method and the b-ELISA method.
Accordingly, the present invention comprises:
1, SEQ ID NO: 1.
SEQ ID NO: 2.
3, SEQ ID NO: 3.
SEQ ID NO: 1 and the polypeptide shown in SEQ ID NO: 2.
5, SEQ ID NO: 1 and the polypeptide shown in SEQ ID NO: 3 in a pharmaceutically acceptable carrier
6. Use of the above polypeptide or combination of polypeptides in the preparation of a kit for detecting the presence of antibodies (IgG) against peste des petits ruminants virus in a biological sample of biological origin from a subject.
7. A peste des petits ruminants virus antibody (IgG) detection kit comprising one or more solid supports, and the following polypeptide combination 1 independently linked to the one or more solid supports;
polypeptide combination 1
SEQ ID NO: 1, and
SEQ ID NO: 2.
8. A peste des petits ruminants virus antibody (IgG) detection kit comprising one or more solid supports, and the following polypeptide combination 2 independently linked to the one or more solid supports;
polypeptide combination 2
SEQ ID NO: 1, and
SEQ ID NO: 3.
9. Peste des petits ruminants virus antibody (IgG) detection kit according to claim 7 or 8, which does not comprise other probe molecules (e.g. polypeptides, proteins or nucleic acids).
10. Use of the polypeptide combination 1 in the preparation of a kit for detecting the presence of antibodies (IgG) against peste des petits ruminants virus in a biological sample of biological origin from a subject;
polypeptide combination 1
SEQ ID NO: 1, and
SEQ ID NO: 2.
11. Use of the polypeptide combination 2 in the preparation of a kit for detecting the presence of antibodies (IgG) against peste des petits ruminants virus in a biological sample of biological origin from a subject;
polypeptide combination 2
SEQ ID NO: 1, and
SEQ ID NO: 3.
The invention also includes:
12, SEQ ID NO: 4.
SEQ ID NO: 5.
14, SEQ ID NO: 1 and the polypeptide shown in SEQ ID NO: 4.
15, SEQ ID NO: 1 and the polypeptide shown in SEQ ID NO: 5.
16. Use of the above polypeptide or combination of polypeptides in the preparation of a kit for detecting the presence of antibodies (IgG) against peste des petits ruminants virus in a biological sample of biological origin from a subject.
17. A peste des petits ruminants virus antibody (IgG) detection kit comprising one or more solid supports, and the following polypeptide combination 1 independently linked to the one or more solid supports;
polypeptide combination 3
SEQ ID NO: 1, and
SEQ ID NO: 4.
18. A peste des petits ruminants virus antibody (IgG) detection kit comprising one or more solid supports, and the following polypeptide combination 2 independently linked to the one or more solid supports;
polypeptide combination 4
SEQ ID NO: 1, and
SEQ ID NO: 5.
19. Peste des petits ruminants virus antibody (IgG) detection kit according to claim 17 or 18, which does not comprise other probe molecules (e.g. polypeptides, proteins or nucleic acids).
20. Use of the following polypeptide combination 3 for the preparation of a kit for detecting the presence of antibodies (IgG) against peste des petits ruminants virus in a biological sample of biological origin from a subject;
polypeptide combination 3
SEQ ID NO: 1, and
SEQ ID NO: 4.
21. Use of the polypeptide combination 4 in the preparation of a kit for detecting the presence of antibodies (IgG) against peste des petits ruminants virus in a biological sample of biological origin from a subject;
polypeptide combination 4
SEQ ID NO: 1, and
SEQ ID NO: 5.
In addition, the present invention further comprises:
22, SEQ ID NO: 6.
SEQ ID NO: 7.
24, SEQ ID NO: 1 and the polypeptide shown in SEQ ID NO: 6.
25, SEQ ID NO: 1, SEQ ID NO: 6 and the polypeptide shown in SEQ ID NO: 7.
26. Use of the above polypeptide or combination of polypeptides in the preparation of a kit for detecting the presence of antibodies (IgG) against peste des petits ruminants virus in a biological sample of biological origin from a subject.
27. A peste des petits ruminants virus antibody (IgG) detection kit comprising one or more solid supports, and the following polypeptide combination 1 independently linked to the one or more solid supports;
polypeptide combination 5
SEQ ID NO: 1, and
SEQ ID NO: 6.
28. A peste des petits ruminants virus antibody (IgG) detection kit comprising one or more solid supports, and the following polypeptide combinations 6 independently linked to the one or more solid supports;
polypeptide combination 6
SEQ ID NO: 1 of a polypeptide represented by the general formula (I),
SEQ ID NO: 6, and
SEQ ID NO: 7.
29. The peste des petits ruminants virus antibody (IgG) detection kit according to claim 27 or 28, which does not comprise other probe molecules (e.g. polypeptides, proteins or nucleic acids).
30. Use of the polypeptide combination 5 in the preparation of a kit for detecting the presence of antibodies (IgG) against peste des petits ruminants virus in a biological sample of biological origin from a subject;
polypeptide combination 5
SEQ ID NO: 1, and
SEQ ID NO: 6.
31. Use of the polypeptide combination 6 in the preparation of a kit for detecting the presence of antibodies (IgG) against peste des petits ruminants virus in a biological sample of biological origin from a subject;
polypeptide combination 6
SEQ ID NO: 1 of a polypeptide represented by the general formula (I),
SEQ ID NO: 6, and
SEQ ID NO: 7.
In the present specification, the subject organism is preferably a small ruminant, more preferably a goat or sheep.
In the present specification, the biological sample may be whole blood, plasma or serum.
The polypeptide and the kit can be used for detecting whether an antibody (IgG) resisting the peste des petits ruminants virus exists in a biological sample of a biological source of a subject. In general, antibodies against peste des petits ruminants virus in a biological sample are produced by infection of a subject organism with peste des petits ruminants virus or immunization with peste des petits ruminants vaccine, and thus the polypeptide and the kit can be used to diagnose whether a subject organism is infected with peste des petits ruminants virus or immunized with peste des petits ruminants vaccine.
Detailed description of the invention
First, the present invention provides SEQ ID NO: 1 to 7, which are useful as a means for detecting the presence or absence of an antibody (IgG) against peste des petits ruminants virus in a biological sample derived from a subject organism. Moreover, the inventors found that SEQ ID NO: 1 alone, the sensitivity and the specificity of the polypeptide for detecting the peste des petits ruminants virus antibody are respectively 70.2% and 99.4%. Compared to the sensitivity of typically not more than 50% for a single polypeptide in an epitope-polypeptide-based indirect ELISA method, the amino acid sequence of SEQ ID NO: 1 is surprising and, therefore, it achieves unexpected technical effects.
In the present specification, sensitivity means: among positive samples confirmed by the "gold standard" method, the proportion of positive samples determined by other methods was determined. The specificity refers to: among negative samples confirmed by the "gold standard" method, the proportion of negative samples was determined by other methods. For the detection of peste des petits ruminants virus antibodies, the "gold standard" in the art is the virus neutralization assay (VNT).
The nucleotide sequence of SEQ ID NO: the polypeptide shown in 1 can be used as a detection probe for preparing a kit for detecting whether an antibody for peste des petits ruminants virus exists in a biological sample of a biological source of a subject.
In addition, the present invention also provides SEQ ID NO: 2-7.
In addition, the invention also provides the following polypeptide combinations 1-6.
Polypeptide combination 1
SEQ ID NO: 1, and
SEQ ID NO: 2.
Polypeptide combination 2
SEQ ID NO: 1, and
SEQ ID NO: 3.
Polypeptide combination 2-1
SEQ ID NO: 1 of a polypeptide represented by the general formula (I),
SEQ ID NO: 2, and
SEQ ID NO: 3.
Polypeptide combination 3
SEQ ID NO: 1, and
SEQ ID NO: 4.
Polypeptide combination 4
SEQ ID NO: 1, and
SEQ ID NO: 5.
Polypeptide combination 4-1
SEQ ID NO: 1 of a polypeptide represented by the general formula (I),
SEQ ID NO: 4, and
SEQ ID NO: 5.
Polypeptide combination 5
SEQ ID NO: 1, and
SEQ ID NO: 6.
Polypeptide combination 6
SEQ ID NO: 1 of a polypeptide represented by the general formula (I),
SEQ ID NO: 6, and
SEQ ID NO: 7.
Polypeptide combination 6-1
SEQ ID NO: 1, and
SEQ ID NO: 7.
The polypeptide is used for detecting whether an antibody for resisting the peste des petits ruminants virus exists in a biological sample of a biological source of a subject, the sensitivity and the specificity are both more than 85 percent (and are verified by a VNT method and not verified by a control kit method), and the c-ELISA method or the b-ELISA method can be compared favorably.
Therefore, the polypeptide combination can be used as a detection probe for preparing a kit for detecting whether the anti-peste des petits ruminants virus antibody exists in a biological sample of a biological source of a subject.
Accordingly, the present invention also provides a peste des petits ruminants virus antibody detection kit comprising one or more solid supports, and one or more of the above combinations of polypeptides independently linked to the one or more solid supports.
In the present specification, the solid support may be one or a plurality of solid supports, but preferably one, that is, all the polypeptides are independently attached to the same solid support. In the present invention, the solid carrier is not particularly limited as long as it is a carrier which is a solid or an insoluble material. The polypeptide can be linked to the solid support by methods known to those skilled in the art.
In the present specification, the subject organism is preferably a small ruminant, more preferably a goat or sheep.
In the present specification, the biological sample may be whole blood, plasma or serum.
In the case of detecting the presence or absence of an antibody against peste des petits ruminants virus in a biological sample of biological origin of a subject using the above-mentioned kit, when any one or more of the polypeptides in the combination of polypeptides responds to the biological sample of biological origin of the subject, it is determined that the antibody against peste des petits ruminants virus is present in the biological sample of biological origin of the subject (i.e., positive); conversely, when none of the polypeptides in the combination of polypeptides is responsive to a biological sample of biological origin of the subject, it is determined that antibodies against peste des petits ruminants virus are not present in the biological sample of biological origin of the subject (i.e., negative).
In the present specification, "response" means: a signal-to-noise ratio (SNR) greater than or equal to 2, wherein signal-to-noise ratio ═ (polypeptide dot signal value-negative control dot signal value)/negative control dot signal value.
Examples
1. Preparation and validation of Polypeptides
SEQ ID NO: the polypeptides 1 to 7 were synthesized by gill biochemical (shanghai) ltd and confirmed by mass spectrometry. Wherein,
SEQ ID NO:1:SAEALFRLQAMAKILEDQEE。
SEQ ID NO:2:TKRTRSGKPRGETPGPLLPE。
SEQ ID NO:3:GETPGPLLPEIMQEDELSRE。
SEQ ID NO:4:TKNVRPIQTLTPGRRTRRFV。
SEQ ID NO:5:SSQNPREAQRSAEALFRLQA。
SEQ ID NO:6:NQDPDKLLTVIASDKCPVVE。
SEQ ID NO:7:TPGRRTRRFVGAVLAGVALG。
2. preparation of kit (detection chip) 1-3
Kit 1
The above-mentioned SEQ ID NO: 1, additionally spotting a goat IgG as a positive quality control point and a PB point as a negative quality control point to prepare the detection chip.
Kit 2
Except that the above-mentioned SEQ ID NOs: 1 and 2, preparing a detection chip according to the same preparation method as the kit 1, namely the kit 2. Kit 3
Except that the above-mentioned SEQ ID NOs: 1 and 3, preparing a detection chip according to the same preparation method as the kit 1, namely the kit 3. Kit 4
Except that the above-mentioned SEQ ID NOs: 1 and 4, preparing a detection chip according to the same preparation method as the kit 1, namely the kit 4. Kit 5
Except that the above-mentioned SEQ ID NOs: 1 and 5, preparing a detection chip according to the same preparation method as the kit 1, namely the kit 5. Kit 6
Except that the above-mentioned SEQ ID NOs: 1 and 6, preparing a detection chip according to the same preparation method as the kit 1, namely the kit 6. Kit 7
Except that the above-mentioned SEQ ID NOs: 1. 6 and 7, preparing a detection chip which is the kit 7 according to the same preparation method as the kit 1.
3. Detection with a kit
Inspection step
(1) Then, 20 Xconcentrated wash (TBST: 0.4M Tris-HCl, 2.74M NaCl, 2% Tween20, pH 7.2. + -. 0.2) was diluted at a ratio of 1:20 with purified water to obtain a wash. To completely wet the surface of the test chip, about 200. mu.L of the cleaning solution was applied to the surface of the test chip using a pipette and the test chip was immersed for a certain period of time.
(2) The serum samples to be tested were diluted 1:50 with a sample diluent (0.05MPBS, 1% BSA, 0.2% PVP, 0.5% Tween20, pH7.2. + -. 0.2).
(3) Then, 200. mu.L of the diluted serum sample was aspirated and added to the detection chip with the surface completely wet, from the detection chip from which the washing solution was discarded.
(4) The detection chip was incubated at 150 rpm for 30 minutes in a constant temperature shaker at room temperature.
(5) And discarding the serum sample, and cleaning the surface of the detection chip by using a cleaning solution.
(6) After washing, 200. mu.L of enzyme-labeled antibody solution (rabbit anti-goat IgG-HRP, Sigma, A5420) was added to the detection chip, and the detection chip was incubated at 150 rpm for 30 minutes in a constant temperature shaker at room temperature.
(7) And discarding the enzyme-labeled antibody solution, and cleaning the surface of the detection chip by using a cleaning solution.
(8) After the completion of the washing, 20. mu.L of a luminescent substrate solution (Thermo, Prod #37074) was uniformly spread on the surface of the detection chip.
(9) And carrying out chemiluminescence imaging on the detection chip by using a gel imager, and judging the result.
(10) And judging the result: for each serum, each polypeptide in the kit was counted for response (i.e., signal-to-noise ratio (SNR) of 2 or more) and judged. That is to say that the first and second electrodes,
for the above kit 1, when SEQ ID NO: 1, when the polypeptide is responsive, judging that the peste des petits ruminants virus antibody is positive; otherwise, the result is judged to be negative.
For the above kit 2, when SEQ ID NO: 1 and/or 2, and determining that the peste des petits ruminants virus antibody is positive; otherwise, the result is judged to be negative.
For the above kit 3, when SEQ ID NO: 1 and/or 3, and judging the peste des petits ruminants virus antibody to be positive when the polypeptide responds; otherwise, the result is judged to be negative.
For the above kit 4, when SEQ ID NO: 1 and/or 4, and judging the peste des petits ruminants virus antibody to be positive when the polypeptide responds; otherwise, the result is judged to be negative.
For the above kit 5, when SEQ ID NO: 1 and/or 5, and determining that the peste des petits ruminants virus antibody is positive; otherwise, the result is judged to be negative.
For the above kit 6, when SEQ ID NO: 1 and/or 6, and determining that the peste des petits ruminants virus antibody is positive; otherwise, the result is judged to be negative.
For the above kit 7, when SEQ ID NO: 1 and/or 6 and/or 7, and determining that the peste des petits ruminants virus antibody is positive; otherwise, the result is judged to be negative.
Wherein, the signal-to-noise ratio is (polypeptide dot signal value-negative control dot signal value)/negative control dot signal value. The polypeptide dot signal value refers to the chemiluminescence intensity value of the polypeptide dot read by software, and the negative control dot signal value refers to the chemiluminescence intensity value of the negative control dot read by software.
755 goat and sheep serum samples from different regions of china were respectively detected by using the kit prepared in step 2 (step 3 above) and the virus neutralization test (VNT, according to the method described in OIE (2010) peste des petits ruminants virus neutralization test), and the detection results are shown below.
TABLE 1
Sensitivity 280/399 100 ═ 70.2% specificity 354/356 ═ 99.4%
TABLE 2
Sensitivity 354/399 100 ═ 88.7% specificity 338/356 ═ 94.9%
TABLE 3
Sensitivity 348/399 × 100 ═ 87.2% specificity ═ 325/356 ═ 91.3%
TABLE 4
Sensitivity 345/399 x 100 ═ 86.5% specificity 339/356 ═ 95.2%
TABLE 5
Sensitivity 342/399 × 100%
Specificity 336/356 94.4%
TABLE 6
Sensitivity 339/399 × 100%
Specificity 330/356 92.7%
TABLE 7
Sensitivity 35539/399 × 100%
Specificity 320/356 89.9%
As can be seen from the above, the sensitivity and specificity of the kits 2-7 are both more than 85% (and are verified by the VNT method, not by the control kit method), which is sufficient to compare with the kits adopting the c-ELISA method or the b-ELISA method.
Sequence listing
<110> Albotuo Biotechnology Ltd, Suzhou
<120> Peste des petits ruminants virus antibody detection kit
<130> PB00133
<160> 7
<170> SIPOSequenceListing 1.0
<210> 1
<211> 20
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 1
Ser Ala Glu Ala Leu Phe Arg Leu Gln Ala Met Ala Lys Ile Leu Glu
1 5 10 15
Asp Gln Glu Glu
20
<210> 2
<211> 20
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 2
Thr Lys Arg Thr Arg Ser Gly Lys Pro Arg Gly Glu Thr Pro Gly Pro
1 5 10 15
Leu Leu Pro Glu
20
<210> 3
<211> 20
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 3
Gly Glu Thr Pro Gly Pro Leu Leu Pro Glu Ile Met Gln Glu Asp Glu
1 5 10 15
Leu Ser Arg Glu
20
<210> 4
<211> 20
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 4
Thr Lys Asn Val Arg Pro Ile Gln Thr Leu Thr Pro Gly Arg Arg Thr
1 5 10 15
Arg Arg Phe Val
20
<210> 5
<211> 20
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 5
Ser Ser Gln Asn Pro Arg Glu Ala Gln Arg Ser Ala Glu Ala Leu Phe
1 5 10 15
Arg Leu Gln Ala
20
<210> 6
<211> 20
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 6
Asn Gln Asp Pro Asp Lys Leu Leu Thr Val Ile Ala Ser Asp Lys Cys
1 5 10 15
Pro Val Val Glu
20
<210> 7
<211> 20
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 7
Thr Pro Gly Arg Arg Thr Arg Arg Phe Val Gly Ala Val Leu Ala Gly
1 5 10 15
Val Ala Leu Gly
20
Claims (10)
1, SEQ ID NO: 1.
SEQ ID NO: 1 in the manufacture of a kit for detecting the presence of antibodies (IgG) against peste des petits ruminants virus in a biological sample of biological origin from a subject.
3. A peste des petits ruminants virus antibody (IgG) detection kit comprising one or more solid supports, and the following polypeptide combination 1 independently linked to the one or more solid supports;
polypeptide combination 1
SEQ ID NO: 1, and
SEQ ID NO: 2.
4. A peste des petits ruminants virus antibody (IgG) detection kit comprising one or more solid supports, and the following polypeptide combination 2 independently linked to the one or more solid supports;
polypeptide combination 2
SEQ ID NO: 1, and
SEQ ID NO: 3.
5. Use of the polypeptide combination 1 in the preparation of a kit for detecting the presence of antibodies (IgG) against peste des petits ruminants virus in a biological sample of biological origin from a subject;
polypeptide combination 1
SEQ ID NO: 1, and
SEQ ID NO: 2.
6. Use of the polypeptide combination 2 in the preparation of a kit for detecting the presence of antibodies (IgG) against peste des petits ruminants virus in a biological sample of biological origin from a subject;
polypeptide combination 2
SEQ ID NO: 1, and
SEQ ID NO: 3.
7. The use according to any one of claims 2, 5, 6 or the kit according to any one of claims 3, 4, wherein the subject organism is a small ruminant.
8. The use according to any one of claims 2, 5, 6 or the kit according to any one of claims 3, 4, wherein the subject organism is a goat or a sheep.
9. The use according to any one of claims 2, 5, 6 or the kit according to any one of claims 3, 4, wherein the biological sample is whole blood, plasma or serum.
10. The kit according to claim 3 or 4, for use in diagnosing whether a subject organism is infected with Peste des petits ruminants virus or immunized with Peste des petits ruminants vaccine.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811121779.7A CN110346567B (en) | 2018-04-03 | 2018-04-03 | Peste des petits ruminants virus antibody detection kit |
CN202010422348.5A CN111537713B (en) | 2018-04-03 | 2018-04-03 | Peste des petits ruminants virus antibody detection kit |
CN201810310284.2A CN110346565B (en) | 2018-04-03 | 2018-04-03 | Peste des petits ruminants virus antibody detection kit |
CN201811121776.3A CN110346566B (en) | 2018-04-03 | 2018-04-03 | Peste des petits ruminants virus antibody detection kit |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810310284.2A CN110346565B (en) | 2018-04-03 | 2018-04-03 | Peste des petits ruminants virus antibody detection kit |
Related Child Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811121776.3A Division CN110346566B (en) | 2018-04-03 | 2018-04-03 | Peste des petits ruminants virus antibody detection kit |
CN201811121779.7A Division CN110346567B (en) | 2018-04-03 | 2018-04-03 | Peste des petits ruminants virus antibody detection kit |
CN202010422348.5A Division CN111537713B (en) | 2018-04-03 | 2018-04-03 | Peste des petits ruminants virus antibody detection kit |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110346565A true CN110346565A (en) | 2019-10-18 |
CN110346565B CN110346565B (en) | 2022-05-24 |
Family
ID=68173563
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811121779.7A Active CN110346567B (en) | 2018-04-03 | 2018-04-03 | Peste des petits ruminants virus antibody detection kit |
CN202010422348.5A Active CN111537713B (en) | 2018-04-03 | 2018-04-03 | Peste des petits ruminants virus antibody detection kit |
CN201810310284.2A Active CN110346565B (en) | 2018-04-03 | 2018-04-03 | Peste des petits ruminants virus antibody detection kit |
CN201811121776.3A Active CN110346566B (en) | 2018-04-03 | 2018-04-03 | Peste des petits ruminants virus antibody detection kit |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811121779.7A Active CN110346567B (en) | 2018-04-03 | 2018-04-03 | Peste des petits ruminants virus antibody detection kit |
CN202010422348.5A Active CN111537713B (en) | 2018-04-03 | 2018-04-03 | Peste des petits ruminants virus antibody detection kit |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811121776.3A Active CN110346566B (en) | 2018-04-03 | 2018-04-03 | Peste des petits ruminants virus antibody detection kit |
Country Status (1)
Country | Link |
---|---|
CN (4) | CN110346567B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110346567B (en) * | 2018-04-03 | 2022-08-12 | 苏州工业园区强东医药科技有限公司 | Peste des petits ruminants virus antibody detection kit |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102419369A (en) * | 2011-08-18 | 2012-04-18 | 云南出入境检验检疫局检验检疫技术中心 | Kit for detecting antibody against Peste des petits ruminants virus b-ELISA and preparation method thereof |
CN102967710A (en) * | 2012-08-03 | 2013-03-13 | 中国农业科学院兰州兽医研究所 | Competitive ELISA kit for peste-des-petits-ruminants antibody detection and preparation method thereof |
CN103308678A (en) * | 2013-05-31 | 2013-09-18 | 艾军 | Sandwiched ELISA (Enzyme-Linked Immunoassay) detection reagent for detecting peste des petits ruminant viruses as well as preparation and use methods of reagent |
CN105158480A (en) * | 2015-08-05 | 2015-12-16 | 中国农业科学院兰州兽医研究所 | Kit for detecting peste des petits ruminants virus hemagglutinin protein antibody and application method of kit |
CN107238702A (en) * | 2017-06-22 | 2017-10-10 | 中国动物疫病预防控制中心 | Detect the enzyme linked immunological kit of PPR virus antibody |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101422607B (en) * | 2008-10-08 | 2011-11-16 | 中国农业科学院哈尔滨兽医研究所 | Peste des petis ruminants recombined goat pox virus movable carrier vaccine |
FR2994697B1 (en) * | 2012-08-24 | 2016-05-13 | Centre De Coop Int En Rech Agronomique Pour Le Dev (Cirad) | VACCINE STRAIN MARKED FROM SMALL RUMINANT FAT VIRUS, AND METHOD OF OBTAINING SAME |
CN104341490A (en) * | 2014-10-10 | 2015-02-11 | 深圳出入境检验检疫局动植物检验检疫技术中心 | Peste des petits ruminants virus recombinant protein antigen and rapid test strip for peste des petits ruminants virus antibody |
CN107098979B (en) * | 2017-06-22 | 2020-05-19 | 中国动物疫病预防控制中心 | Peste des petits ruminants virus H-F fusion protein and related biological material and application thereof |
CN107033225B (en) * | 2017-06-27 | 2024-05-14 | 中国农业科学院兰州兽医研究所 | Peste des petits ruminants virus HN protein epitope peptide and determination, preparation method and application thereof |
CN107216372B (en) * | 2017-06-27 | 2020-09-04 | 中国农业科学院兰州兽医研究所 | Peste des petits ruminants virus HN protein epitope peptide H362, determination method, preparation method and application thereof |
CN110346567B (en) * | 2018-04-03 | 2022-08-12 | 苏州工业园区强东医药科技有限公司 | Peste des petits ruminants virus antibody detection kit |
-
2018
- 2018-04-03 CN CN201811121779.7A patent/CN110346567B/en active Active
- 2018-04-03 CN CN202010422348.5A patent/CN111537713B/en active Active
- 2018-04-03 CN CN201810310284.2A patent/CN110346565B/en active Active
- 2018-04-03 CN CN201811121776.3A patent/CN110346566B/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102419369A (en) * | 2011-08-18 | 2012-04-18 | 云南出入境检验检疫局检验检疫技术中心 | Kit for detecting antibody against Peste des petits ruminants virus b-ELISA and preparation method thereof |
CN102967710A (en) * | 2012-08-03 | 2013-03-13 | 中国农业科学院兰州兽医研究所 | Competitive ELISA kit for peste-des-petits-ruminants antibody detection and preparation method thereof |
CN103308678A (en) * | 2013-05-31 | 2013-09-18 | 艾军 | Sandwiched ELISA (Enzyme-Linked Immunoassay) detection reagent for detecting peste des petits ruminant viruses as well as preparation and use methods of reagent |
CN105158480A (en) * | 2015-08-05 | 2015-12-16 | 中国农业科学院兰州兽医研究所 | Kit for detecting peste des petits ruminants virus hemagglutinin protein antibody and application method of kit |
CN107238702A (en) * | 2017-06-22 | 2017-10-10 | 中国动物疫病预防控制中心 | Detect the enzyme linked immunological kit of PPR virus antibody |
Non-Patent Citations (1)
Title |
---|
JINGYUE BAO 等: "Complete Genome Sequence of a Novel Variant Strain of Peste des Petits Ruminants Virus, China/XJYL/2013", 《GENOME ANNOUNCEMENTS》 * |
Also Published As
Publication number | Publication date |
---|---|
CN111537713B (en) | 2023-03-24 |
CN110346567A (en) | 2019-10-18 |
CN110346567B (en) | 2022-08-12 |
CN110346566A (en) | 2019-10-18 |
CN110346565B (en) | 2022-05-24 |
CN110346566B (en) | 2022-04-12 |
CN111537713A (en) | 2020-08-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106596966B (en) | A kind of ox aftosa 3ABC antibody chemical luminescence detection kit | |
CN108101968B (en) | Peste des petits ruminants vaccine strain and wild strain differential synthetic peptide and application thereof | |
CN110346565B (en) | Peste des petits ruminants virus antibody detection kit | |
CN112213493B (en) | Peste des petits ruminants detection kit capable of being used for distinguishing vaccine immunity from natural infection | |
CN108956986B (en) | Newcastle disease virus antibody detection kit | |
CN110498843B (en) | Peste des petits ruminants diagnostic kit | |
CN110498845B (en) | Peste des petits ruminants diagnostic kit | |
KR101032956B1 (en) | Rapid diagnostic kit of hemorrhagic fever with renal syndrome detecting specific IgM and IgG using nucleocapsid protein derived from Soochong virus | |
CN112321706B (en) | Monoclonal antibody and diagnostic kit for diagnosing Peste des petits ruminants | |
CN110498842B (en) | Peste des petits ruminants diagnostic kit | |
CN110498844B (en) | Peste des petits ruminants diagnostic kit | |
CN110488011B (en) | Newcastle disease virus antibody detection kit | |
CN110373501A (en) | A kind of Porcine epidemic diarrhea virus quick detection kit based on biomolecular | |
CN110488017B (en) | Newcastle disease virus antibody detection kit | |
CN110501505B (en) | Peste des petits ruminants diagnostic kit | |
CN110488010B (en) | Newcastle disease virus antibody detection kit | |
CN108693352B (en) | Newcastle disease virus antibody detection kit | |
KR102254697B1 (en) | Kit of detection for Foot and mouth disease virus with immono-polymerase chain reaction and method thereof | |
CN115160412A (en) | Peste des petits ruminants virus antibody detection kit | |
TWI308959B (en) | ||
CN110531080B (en) | Newcastle disease virus antibody detection kit | |
CN110531081B (en) | Newcastle disease virus antibody detection kit | |
KR20150079571A (en) | Method of detection of schmallenberg virus (sbv) and kit |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |